A pioneering Regenerative Macrophage Therapy (RMT) could represent a new method of treating end-stage liver disease, research shows. 

Results from the University of Edinburgh’s MATCH trial, published in Cell Stem Cell, demonstrate RMT provides significantly prolonged transplant‑free survival after four years compared with those who received standard care. 

Four-year follow-up data from the trial also show this form of RMT has a favourable safety and tolerability profile, with no evidence of increased serious adverse events. 

Biopharmaceutical company Resolution Therapeutics, whose founder Professor Stuart Forbes led the trial, welcomed the findings as it looks to progress a Phase I/II trial for its engineered RMT RTX001. 

The therapy, being evaluated in patients with end-stage liver disease who have a history of decompensated liver cirrhosis, has been developed using patients’ macrophages enhanced with IL-10 and MMP9 to deliver superior anti-inflammatory and anti-fibrotic activity. 

“All of us at Resolution Therapeutics would like to congratulate Professor Stuart Forbes and his University of Edinburgh team on this important clinical milestone,” Dr Clifford Brass, Chief Medical Officer of Resolution Therapeutics. 

“Our work at Resolution would not have been possible without their foundational research. The MATCH four-year data reinforce the scientific rationale for Regenerative Macrophage Therapies to address inflammation and fibrosis in the liver, targeting a clear and significant unmet medical need.  

“We look forward to the interim results from the EMERALD study – testing RTX001, our engineered RMT, in patients with end-stage liver disease – later this year.”